Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients
|
|
- Allen Park
- 6 years ago
- Views:
Transcription
1 Emerging Treatments and Technologies O R I G I N A L A R T I C L E Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients KLAUS RAVE 1 TIM HEISE 1 ANDREAS PFÜTZNER 2 1 LUTZ HEINEMANN PETER T. SAWICKI 3 OBJECTIVE To quantify properties of regular insulin and insulin lispro in type 1 diabetic patients with and without overt diabetic. RESEARCH DESIGN AND METHODS In this double-blind, two-way cross-over, euglycemic (5 mmol/l) glucose clamp study, we investigated the metabolic response to subcutaneous injections of regular insulin and insulin lispro (0.2 U/kg) in 12 type 1 diabetic patients with overt diabetic (proteinuria 500 mg/24 h and/or serum creatinine 1.5 mg/dl; NP group) and in a control group of 12 type 1 diabetic patients with normal renal function (DC group). RESULTS Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups. Overall insulin levels for regular insulin and for insulin lispro were higher in patients with overt diabetic compared with control patients. Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]). The overall metabolic effect of regular insulin but not of insulin lispro was lower in patients with diabetic than in diabetic control patients (967 vs. 1,510 mg/kg, respectively). CONCLUSIONS Although insulin levels are higher in patients with overt diabetic, the metabolic response to regular insulin is reduced. Insulin lispro maintains its characteristic properties in patients with overt diabetic. Insulin therapy in type 1 diabetic patients with overt diabetic is characterized by two features: while suffering from a considerably increased risk of severe hypoglycemic episodes (1,2), they show poorer metabolic control than diabetic patients with normal renal Diabetes Care 24: , 2001 function (3). The increased hypoglycemic risk may be partially explained by the decline in renal insulin clearance, as 30 80% of systemically circulating insulin is removed by the kidneys (4). A reduction of insulin clearance has been described in nondiabetic patients with end-stage renal From the 1 Profil Institute for Metabolic Research, Neuss; 2 Institut für Klinische Forschung und Entwicklung, Mainz; and 3 St. Franziskus Hospital, Cologne, Germany. Address correspondence and reprint requests to Dr. Klaus Rave, Profil Institute for Metabolic Research GmbH, Stresemannallee 6, 41460, Neuss, Germany. klaus.rave@profil-research.de. Received for publication 31 October 2000 and accepted in revised form 18 January Abbreviations: AUC, area under the curve; GIR, glucose infusion rate; INS, insulin. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. failure (5,6) and mild to moderate renal impairment (7); however, until now, it has not been studied in patients with diabetic. Insulin sensitivity, on the other hand, is attenuated in patients with renal impairment, not only in those with endstage renal failure, but also in patients in earlier stages of renal impairment (7 9). However, to date the metabolic consequences of reduced insulin clearance and diminished insulin sensitivity on pharmacokinetic and pharmacodynamic properties of regular insulin or rapid acting insulin analogues have never been studied in type 1 diabetic patients. In view of the diminished clearance of insulin in patients with altered renal function, the use of a rapid-acting insulin analogue might theoretically be advantageous because of its shorter duration of action, leading to a reduced incidence of hypoglycemic episodes (10,11). Therefore, the aim of this study was to quantify summary measures for regular insulin and insulin lispro in type 1 diabetic patients with and without overt diabetic. RESEARCH DESIGN AND METHODS Patients For this study, 12 type 1 diabetic patients fulfilling the following inclusion criteria were recruited: age years; GHb 10%; overt diabetic (defined according to the modified Mogensen criteria: proteinuria 500 mg/24 h on repeated measurements and/or serum creatinine 1.5 mg/dl [122 mol/l] with no clinical or laboratory evidence of renal or urinary tract disease other than diabetic glomerulosclerosis) (12); negative insulin-antibody screening; and a negative pregnancy test in women with childbearing potential. The control group consisted of 12 type 1 diabetic patients 886 DIABETES CARE, VOLUME 24, NUMBER 5, MAY 2001
2 Rave and Associates Table 1 Baseline characteristics of type 1 diabetic patients with and without overt diabetic Characteristic Patients with without ; that is, their protein excretion and endogenous creatinine clearance were within the normal range (Table 1). Patients with overt diabetic were older and had a longer duration of diabetes than patients without (29 vs. 18 years). The mean HbA 1c was higher in patients with diabetic, whereas the mean daily insulin dosage was comparable for both groups of patients. According to the inclusion criteria, patients with overt diabetic showed higher serum creatinine levels and lower glomerular filtration rates. This randomized study was performed in a double-blind fashion (study medication was applied by a person otherwise not involved in the study). The study protocol was approved by the local ethical committee and was carried out according to the guidelines of Good Clinical Practice. After detailed oral and written explanation of the study objectives, all patients gave their written informed consent to participate in the study. After a fasting interval of 12 h, patients arrived at our institute in the morning ( 8:00 A.M.) and were connected to a Biostator (Life Science Instruments, Elkhart, IN). The left hand was placed in a box that was warmed to an air temperature of 55 C to allow the sampling of arterialized venous blood. Fasting blood glucose of the patients was lowered during the first 60 min of a 4-h run-in period by means of an insulin infusion to a target level of 5.0 mmol/l (90 mg/dl). After having reached this target level, blood glucose was kept constant Patients without Sex (female/male, n) 6/6 3/ Age (years) Weight (kg) BMI (kg/m 2 ) Duration of diabetes (years) HbA 1c (%) Serum creatinine ( mol/l) GFR (ml/min/[1.73 m 2 ]) Proteinuria (mg/24 h) Daily insulin dosage (U/day) Data are means SD or frequencies. GFR, glomerular filtration rate. over the next 180 min by adapting the dosage of a continuous intravenous insulin infusion. At the end of the run-in period ( 12:00 P.M.), patients received subcutaneous injections of 0.2 U/kg body wt of either regular human insulin (Humulin U 100; Lilly Deutschland, Bad Homburg, Germany) or insulin lispro (Humalog U 100; Lilly Deutschland); patients with received U (mean SD) and diabetic control subjects received U into a lifted skinfold in the abdominal region. Thereafter, an 8-h euglycemic glucose clamp was established, as described in detail elsewhere (13). Mean blood glucose levels during glucose clamps in patients with overt diabetic were mmol/l with regular insulin and mmol/l with insulin lispro. For diabetic control patients, mean blood glucose was mmol/l with regular insulin and mmol/l with insulin lispro during the glucose clamp experiments. All patients were on an intensified insulin therapy before the study and were instructed to take their last short-acting insulin injection in the evening and their long-acting insulin injection at the latest 24 h before the glucose clamp experiments. Insulin pump treated patients were asked to stop the insulin infusion at 6:00 A.M. on the day of the glucose clamp. To exclude ongoing carbohydrate absorption during the time of the glucose clamp, which may occur in patients with severely impaired gastric emptying, a modified 13 C-labeled octanoid acid breath test was performed before every P glucose clamp (14). In brief, patients gave a baseline breath sample in an aluminumcoated bag in the evening preceding the glucose clamp. Thereafter, they ingested a test meal including a scrambled egg with the yolk supplemented with 0.1 ml 13 C-octanoid acid (Wagner Analysen Technik, Bremen, Germany) at 8:00 P.M. Additional breath samples were collected the next morning and after completion of the glucose clamp run-in period. All three samples were analyzed for their 13 C/ 12 C ratio using an infrared isotope analyzer (Iris Infrared Isotope Analyzer; Wagner Analysen Technik). A 13 C/ 12 C ratio 2.5% above baseline would be regarded as a sign of an ongoing carbohydrate absorption attributable to delayed gastric emptying. In those cases, that particular experiment would have to be excluded from further analysis. However, this was never necessary. Blood glucose was measured by a glucose oxidase method (Super G Ambulance, RLT Möhnesee, Germany). HbA 1c was measured with high-performance liquid chromatography (Diamat, Munich, Germany; reference range, %). Proteinuria was determined by means of a laser turbidimetric method (Laserphotometer pm4, Lasermed GmbH, Cologne, Germany) in 24-h urine samples. The glomerular filtration rate was assessed by endogenous creatinine clearance in 24-h urine samples, corrected to 1.73 m 2 body surface. Plasma concentrations of free regular insulin and free insulin lispro were determined after polyethylene glycol precipitation of antibody bound insulin by means of a commercial radioimmunoassay kit (DPC Coat-A-Count Insulin Radioimmunoassay; DPC, Bad Nauheim, Germany; inter- and intraassay coefficients of variation 15.0 and 6.6%, respectively). This assay has recently been validated for the determination of free human insulin and free insulin lispro with similar sensitivity (15). Insulin-antibodies were determined by means of a radioligand assay (CentAK, Medipan Diagnostika, Selchow, Germany). Statistics A polynomial function of sixth order was fitted to the individual glucose infusion rate (GIR) and free insulin profiles, allowing the calculation of pharmacokinetic and pharmacodynamic summary measures. The area under the curve (AUC) for DIABETES CARE, VOLUME 24, NUMBER 5, MAY
3 Diabetic and insulin Figure 1 A: Plasma free insulin levels after subcutaneous injection of 0.2 U/kg regular insulin ( ) and insulin lispro (F) in type 1 diabetic patients with overt diabetic. Thick lines indicate free insulin concentrations; thin lines indicate fitted polynomial function of sixth order. Data represented are means SE. B: Plasma free insulin levels after injection of 0.2 U/kg regular insulin (f) and insulin lispro (E) in type 1 diabetic patients without diabetic. Thick lines indicate free insulin concentrations; thin lines indicate fitted polynomial function of sixth order. C: Fitted polynomial function of sixth order to glucose infusion rate after subcutaneous injection of 0.2 U/kg regular insulin (heavy black line) and insulin lispro (dotted line) in type 1 diabetic patients with overt diabetic. Thin lines indicate glucose infusion rate original registration. D: Fitted polynomial function of sixth order to glucose infusion rate after subcutaneous injection of 0.2 U/kg regular insulin (heavy black line) and insulin lispro (dotted line) in type 1 diabetic patients without diabetic. Thin lines indicate glucose infusion rate original registration. GIR and free insulin was calculated by the trapezoid rule. Wilcoxon s signed-rank test was used for within-group statistical analyses, and the Mann-Whitney U test was applied for between-group comparisons. Multiple regression analyses were performed by using the summary measures as response variables and status, diabetes duration, and HbA 1c as explanatory factors. The aim of these analyses was to assess the impact of diabetic adjusted to diabetes duration and HbA 1c on the response variables. Because of the exploratory character of the study, no adjustments for multiple comparisons were performed. With multiple regression analyses, only the overall metabolic activity for regular insulin in patients without diabetic was significantly associated with a parameter other than the status (i.e., HbA 1c ). For statistical calculations, StatView 5.0 (SAS Institute, Cary, NC) was used. P 0.05 was considered statistically significant. Results are given as means SD throughout the text and as means SE in the figure. RESULTS Peak free plasma insulin levels (INS max ) were higher and time to maximal insulin concentration (t INS max ) was shorter after subcutaneous administration with insulin lispro than after injection of regular insulin in diabetic patients with (P for both) and without (P 0.02 and P 0.006, respectively) (Fig. 1A and B; Table 2). Accordingly, insulin AUCs for the first 3 h after injection were higher with insulin lispro than with regular insulin in both patient groups (P and P 0.005, respectively). When comparing nephropathic patients with the diabetic control subjects, both with regular insulin and with insulin lispro, peak free plasma insulin levels and the insulin AUCs for the intervals 0 3 h and 0 8 h were higher in patients with overt diabetic (regular insulin: P for free plasma insulin, P for 0 3 h AUC, and P for 0 8 h AUC; insulin lispro: P for free plasma insulin, P for 0 3 h AUC, and P for 0 8 h AUC). In contrast, time to late half maximal insulin concentration (late t INS 50% ) for regular insulin and insulin lispro did not differ 888 DIABETES CARE, VOLUME 24, NUMBER 5, MAY 2001
4 Rave and Associates Table 2 Pharmacokinetic and pharmacodynamic summary measures in 12 type 1 diabetic patients with overt diabetic and 12 diabetic patients without diabetic Regular insulin significantly between the group of patients with and without. Comparing the metabolic activity of regular insulin with insulin lispro, the maximal metabolic effect of subcutaneously injected insulin lispro was higher (P 0.003) than the effect of regular insulin in patients with overt diabetic, and tended to be higher (P 0.078) in patients without (Fig. 1C and D; Table 2). Time to maximal metabolic effect (t GIR max ), time to early half maximal activity (early t GIR 50% ), and time to late half maximal activity (late t GIR 50% ) were significantly shorter with insulin lispro than with regular insulin in both patient groups (patients with : P for t GIR max, P 0.03 for early t GIR 50%, and P for late t GIR 50% ; diabetic control subjects: P for t GIR max, P 0.02 for early t GIR 50%, and P for late t GIR 50% ). The metabolic activity during the first 3 h after injection (AUC GIR 0 3 h ) with insulin lispro was higher than with regular insulin in patients with overt diabetic (P 0.004). However, the metabolic activity 4 8 h after administration of insulin (AUC GIR 4 8 h ) was higher for regular insulin than for insulin lispro Patients with Insulin lispro Regular insulin Patients without Insulin lispro INS max (pmol/l) * * t INS max (min) * * Early t INS 50% (min) * Late t INS 50% (min) * * AUC INS 0 3 h (nmol/l) * * AUC INS 0 8 h (nmol/l) * GIR max (mg kg 1 min 1 ) t GIR max (min) * * Early t GIR 50% (min) * * Late t GIR 50% (min) * * AUC GIR 0 3 h (mg/kg) * AUC GIR 0 8 h (mg/kg) AUC GIR 4 8 h (mg/kg) * * AUC GIR 0 8 h /AUC INS 0 8 h *P 0.05 for within-group comparison (patients with overt diabetic or diabetic patients without ) between insulin lispro and regular insulin; P 0.05 for between-group comparison for regular insulin or for insulin lispro. INS max, maximal plasma free insulin concentration; t INSmax, time to maximal free insulin concentration; early/late t INS 50%, time to early/late half-maximal insulin concentration; AUC INS 0 3 h, AUC for free insulin concentration 0 3 h; GIR max, maximal glucose infusion rate; t GIR max, time to GIR max ; early/late t GIR 50%, time to early/late half-maximal glucose infusion rate; AUC GIR 0 3 h, AUC for glucose infusion rate 0 3 h. in both patient groups (P 0.02 for patients with vs for diabetic control subjects). When comparing patients with overt diabetic with diabetic control subjects, the maximal metabolic effect (GIR max ) for regular insulin was lower (P 0.03) and metabolic activity 3 and 8 h after administration of insulin was smaller (P 0.05 and P 0.05, respectively) in patients with overt diabetic than in patients without renal impairment. It is noteworthy that the lower metabolic effect of regular insulin in patients with overt diabetic was in contrast to the higher insulin levels observed in these patients. Glucose consumption per plasma insulin level (Table 2) was significantly lower in diabetic patients with overt than in control subjects with insulin lispro or regular insulin (P and P 0.03, respectively). CONCLUSIONS This study demonstrates for the first time that plasma insulin levels the maximal insulin concentration and insulin levels during 8 h after subcutaneous injection of regular insulin and insulin lispro were higher in patients with diabetic than in diabetic control patients without. This finding suggests a 30 40% reduction of insulin clearance in patients with overt diabetic compared with diabetic patients without. Paradoxically, in spite of higher circulating insulin levels, both the peak metabolic effect and the overall metabolic activity of regular insulin were diminished in patients with overt diabetic when compared with diabetic patients without renal impairment. Because of the lower metabolic response to subcutaneous regular insulin, patients with overt diabetic would have to inject a higher dosage of regular insulin to achieve a metabolic effect comparable with that of nonnephropathic patients. Based on the metabolic activity of regular insulin observed in this study, it can be calculated that a 50% higher dosage is necessary for patients with to achieve the same metabolic effect as diabetic patients with normal renal function. With increasing dosages of regular insulin, however, it has been shown that not only the maximal metabolic response but also the duration of action (i.e., the overall blood glucose lowering effect) increases (16). The prolongation of action with higher insulin dosages, in turn, may increase the risk for late postprandial hypoglycemic episodes. Therefore, the necessity for higher dosages of regular insulin with the resulting prolonged effect may partially explain the substantially higher risk for severe hypoglycemia in patients with diabetic (2). In our study, patients with overt diabetic had a slightly, but not significantly, lower daily insulin dosage compared with diabetic patients without. At first glance, this observation contradicts our finding that diabetic patients with overt diabetic need higher dosages of insulin to achieve the same metabolic effect as patients without renal impairment. However, patients with overt in this study not only injected less insulin, but at the same time exhibited a metabolic control significantly worse than that of diabetic control patients, thus confirming the reduced response to insulin. In the group of patients with overt diabetic, we included subjects exhibiting macroproteinuria and/or elevated serum creatinine. Hence, in pa- DIABETES CARE, VOLUME 24, NUMBER 5, MAY
5 Diabetic and insulin tients classified as having, 10 of 12 subjects showed proteinuria 500 mg/24 h and 7 of 12 patients exhibited serum creatinine 1.5 mg/dl (122 mol/l). One may speculate that in nephropathic patients with moderate to severe renal impairment (serum creatinine 1.5 mg/dl), insulin clearance and/or insulin action that is, pharmacokinetic and pharmacodynamic parameters may have been different compared with patients with but with normal glomerular filtration rate or only mild renal impairment. Therefore, we analyzed the results for these two subgroups of patients in our study separately and interestingly did not find any statistically significant differences between both patient groups. An important finding of this study is that insulin lispro, in comparison to regular insulin, maintained its characteristic properties in patients with overt diabetic. Given that it has been demonstrated that the duration of action of insulin lispro, in contrast to regular insulin, only moderately increases with higher dosages (16), it seems possible that fastacting insulin analogues like insulin lispro and insulin aspart could be of particular advantage in patients with diabetic in reducing the risk of hypoglycemia (17). However, this remains to be shown in adequate clinical studies. The increased risk of patients with overt diabetic for severe hypoglycemic episodes cannot be explained simply by a prolonged duration of insulin action attributable to reduced insulin clearance. In fact, the time to late half maximal insulin concentrations for both regular insulin and insulin lispro was not higher in patients with. More important, the duration of metabolic activity in terms of time to late t GIR 50% was similar for either insulin formulation in patients with and without overt diabetic. Apart from the altered metabolism of insulin and the reduced insulin action, the contribution of the kidneys to gluconeogenesis in the postabsorptive state has to be taken into account in patients with renal impairment (18). Results of two studies in type 1 and type 2 diabetic patients indicate that renal glucose production in the diabetic state per se is increased and accounts for 30% of the overall gluconeogenetic capacity (19, 20). It seems sensible to assume that renal gluconeogenetic capacity decreases with declining renal function, which, consequently, would increase the risk of hypoglycemia in these patients. In summary, we have shown that peak insulin concentrations and overall insulin levels were higher in patients with overt diabetic than in diabetic patients with normal renal function. In contrast to the higher insulin levels, the overall metabolic response to regular insulin but not to insulin lispro was lower in patients with diabetic as in diabetic control patients. The promising results of insulin lispro in patients with overt diabetic should promote clinical studies aimed at reducing the hypoglycemic risk and improvement of metabolic control in these patients (11). Acknowledgments This study was partly supported by a research grant from Lilly Deutschland, Bad Homburg, Germany. We gratefully acknowledge the excellent technical assistance of Uta Eckers, Till Schroer, Andre Feldmann, and Claudia Gottschalk. Our special thanks go to Dr. Ralf Bender for his valuable advice in statistical questions. References 1. Arem R: Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 18: , Mühlhauser I, Toth G, Sawicki PT, Berger M: Severe hypoglycemia in type 1 diabetic patients with impaired kidney function. Diabetes Care 14: , Bending JJ, Pickup JC, Viberti GC, Keen H: Glycaemic control in diabetic. BMJ 288: , Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 27: , Mak RH: Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol 270:F839 F844, DeFronzo RA, Tobin JD, Rowe JW, Andres R: Glucose intolerance in uremia: quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 62: , Eidemak I, Feldt RB, Kanstrup IL, Nielsen SL, Schmitz O, Strandgaard S: Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 38: , DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J: Insulin resistance in uremia. J Clin Invest 67: , Schmitz O, Alberti KG, Christensen NJ, Hasling C, Hjollund E, Beck-Nielsen H, Orskov H: Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism 34: , Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43: , Jehle PM, Aisenpreis U, Bundschu D, Keller F: Vorteile von Insulin Lispro bei terminaler Niereninsuffizienz. Fortschr Med 117:41 42, Sawicki PT, Bender R, Berger M, Mühlhauser I: Non-linear effects of blood pressure and glycosylated hemoglobin on progression of diabetic. J Intern Med 247: , Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S, Heinemann L: Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. Diabet Med 15: , Pfaffenbach B, Wegener M, Adamek RJ, Wissuwa H, Schaffstein J, Aygen S, Hennemann O: Nicht-invasiver 13C- Oktansaureatemtest zur Messung der Magenentleerung einer festen Testmahlzeit Korrelation mit der Szintigraphie bei Diabetikern und Reproduzierbarkeit bei gesunden Probanden. Z Gastroenterol 33: , Burge MR, Mcleod J, Bowsher R, Schade DS: Validity of Coat-A-Count insulin RIA kit for quantifying total and free Humalog. Clin Chem 42:777, Heinemann L, Woodworth J: Pharmacokinetics and glucodynamics of insulin lispro. Drugs of Today 34:23 36, Trajanoski Z, Wach P, Kotanko P, Ott A, Skraba F: Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues. Biomed Tech 38: , Stumvoll M, Meyer C, Mitrakou A, Nadkarni V, Gerich JE: Renal glucose production and utilization: new aspects in humans. Diabetologia 40: , Mitrakou A, Plantanisiotis D, Vlachos L, Mourikis D, Meyer C, Chinatalapudi UY, Gutierrez O, Kreider M, Gerich J: Increased renal glucose production in insuin dependent diabetes (IDDM): contribution to systemic glucose appearance and effect of insulin repletion. Diabetes 45: 33A, Stumvoll M, Perriello G, Nurjhan N, Bucci A, Welle S, Jansson PA, Dailey G, Bier D, Jenssen T, Gerich J: Glutamine and alanine metabolism in NIDDM. Diabetes 45: , DIABETES CARE, VOLUME 24, NUMBER 5, MAY 2001
Diabetes Care Publish Ahead of Print, published online June 22, 2007
Diabetes Care Publish Ahead of Print, published online June 22, 2007 Coverage of Postprandial Blood Glucose Excursions With Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular
More informationA novel ph-neutral formulation of the monomeric insulin VIAject has a faster onset of action than insulin lispro
A novel ph-neutral formulation of the monomeric insulin VIAject has a faster onset of action than insulin lispro Leszek Nosek, Tim Heise, Frank Flacke 2, Alan Krasner 2, Philip Pichotta 2, Lutz Heinemann,
More informationDiabetes Care Publish Ahead of Print, published online June 1, 2009
Diabetes Care Publish Ahead of Print, published online June 1, 2009 Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human
More informationDiabetes Care Publish Ahead of Print, published online November 18, 2008
Diabetes Care Publish Ahead of Print, published online November 18, 2008 Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth with TIDM
More informationSUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
More informationTime-Action Profile of the Long-Acting Insulin Analog Insulin Glargine (HOE901) in Comparison With Those of NPH Insulin and Placebo
Emerging Treatments and O R I G I N A L A R T I C L E Technologies Time-Action Profile of the Long-Acting Insulin Analog Insulin Glargine (HOE901) in Comparison With Those of NPH Insulin and Placebo LUTZ
More informationCohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8)
Supplementary Table. Participant characteristics in cohort Cohort Number Sex, Male Female Age, years. (.) Diabetes duration, years.5 (5.) BMI, kg.m. (3.) HbA c, % mmol.mol. (.7) () C-peptide, nmol.l.3
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationCross-Matches for Bioequivalence Evaluation Division using Needle Free Jet Injector (Comfort-In) and conventional Pen type syringe.
Cross-Matches for Bioequivalence Evaluation Division using Needle Free Jet Injector (Comfort-In) and conventional Pen type syringe. Dr. EunJig, Lee http://www.yuhs.or.kr/en/hospitals/severance/clinic_dept/endo_dept/phy_directory/docprofile.asp?sno=1734
More informationAntisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Digenio A, et al. Table of Contents Detailed Methods for Clinical
More informationassociated with serious complications, but reduce occurrences with preventive measures
Wk 9. Management of Clients with Diabetes Mellitus 1. Diabetes Mellitus body s inability to metabolize carbohydrates, fats, proteins hyperglycemia associated with serious complications, but reduce occurrences
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationDAVID HOPKINS, MRCP JONATHAN M. JANES, MRCP STEPHANIE A. AMIEL, FRCP. Diabetes Care 21: , 1998
E m e r g i n g T r e a t m e n t s a n d T e c h n o l o g i e s N A L A R T I C L E The Action Profile of Lispro Is Not Blunted by Mixing in the Syringe With NPH Insulin STONNY E.JOSEPH, MRCP ANNA KORZON-BURAKOWSKA,
More informationPranay wal et al, /J. Pharm. Sci. & Res. Vol.2(5), 2010,
Comparative efficacy of humalog mix 75/25 with human Insulin. Pranay wal 1 *, Ankita wal 2, Shivangi Srivastava 2,Abhinav srivastava 2, Umeshwar Pandey 3, Tarun Jain 1, Awani k Rai 2. 1 Jodhpur National
More informationDiabetes Care 34: , 2011
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology ELSEMIEK E.C.
More informationNovel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationImproved Postprandial Glucose Control Using the InsuPad Device in Insulin- Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control
578881DSTXXX10.1177/1932296815578881Journal of Diabetes Science and TechnologyRaz et al research-article2015 Original Article Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-
More informationProviding Stability to an Unstable Disease
Basal Insulin Therapy Providing Stability to an Unstable Disease Thomas A. Hughes, M.D. Professor of Medicine - Retired Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health
More informationThe snack is critical for the blood glucose profile during treatment with regular insulin preprandially
Journal of Internal Medicine 1999; 245: 41 45 The snack is critical for the blood glucose profile during treatment with regular insulin preprandially A.-C. ORRE-PETTERSSON, T. LINDSTRÖM, V. BERGMARK &
More information28 Regulation of Fasting and Post-
28 Regulation of Fasting and Post- Prandial Glucose Metabolism Keywords: Type 2 Diabetes, endogenous glucose production, splanchnic glucose uptake, gluconeo-genesis, glycogenolysis, glucose effectiveness.
More informationSCIENTIFIC DISCUSSION
London, 5 October 2005 Product name: NovoMix Procedure No. EMEA/H/C/308/X/18 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationDemonstrating that inhaled insulin
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Dose-Response Relationships of Inhaled Insulin Delivered via the Aerodose Insulin Inhaler and Subcutaneously Injected Insulin in Patients
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationSYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22
SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information75% INSULIN LISPRO PROTAMINE SUSPENSION AND 25% INSULIN LISPRO INJECTION (rdna ORIGIN) 100 UNITS PER ML (U-100)
1 PV 5552 AMP HUMALOG Mix75/25TM 75% INSULIN LISPRO PROTAMINE SUSPENSION AND 25% INSULIN LISPRO INJECTION (rdna ORIGIN) 100 UNITS PER ML (U-100) DESCRIPTION Humalog Mix75/25 [75% insulin lispro protamine
More informationInhaled Technosphere Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes
Journal of Diabetes Science and Technology Volume 2, Issue 2, March 2008 Diabetes Technology Society ORIGINAL ARTICLES Inhaled Technosphere Insulin in Comparison to Subcutaneous Regular Human Insulin:
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationBioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200 U/mL Relative to Insulin Lispro (Humalog W ) 100 U/mL
Original Article Bioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200 U/mL Relative to Insulin Lispro (Humalog W ) 100 U/mL Clinical Pharmacology in Drug Development 2016, 5(1) 69 75 2015
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationBon Secours Richmond Pharmacy & Therapeutics Committees Biphasic Insulin Mixes: Humalog Mix 75/25, NovoLog Mix 70/30, Novolin 70/30
Bon Secours Richmond Pharmacy & Therapeutics Committees Biphasic Insulin Mixes: Humalog Mix 75/25, NovoLog Mix 70/30, Novolin 70/30 Recommendations: MEC Approved MRMC, SMH NovoLog Mix 70/30 will be used
More informationThe oral meal or oral glucose tolerance test. Original Article Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol
Original Article Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol Minimal Model Assessment of -Cell Responsivity and Insulin Sensitivity in Nondiabetic Individuals Chiara Dalla Man,
More informationDose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro KLAUS M. RAVE, MD 1 LESZEK NOSEK, MD 1
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationComparison of Bedtime NPH Insulin Or Metformin Combined with Glibenclamide in Secondary Suiphonylurea Failure in Obese Type H (NIDDM) Patients
Comparison of Bedtime NPH Insulin Or Metformin Combined with Glibenclamide in Secondary Suiphonylurea Failure in Obese Type H (NIDDM) Patients Abstract Pages with reference to book, From 336 To 338 Rauf
More informationReceived: 15 December 2004 / Accepted: 16 May 2005 / Published online: 14 September 2005 # Springer-Verlag 2005
Diabetologia (2005) 48: 1988 1995 DOI 10.1007/s00125-005-1916-y ARTICLE H. E. Scholtz. S. G. Pretorius. D. H. Wessels. R. H. A. Becker Pharmacokinetic and glucodynamic variability: assessment of insulin
More informationIs Degludec the Insulin of Tomorrow?
5 : 6 Nihal Thomas, Ron Thomas Varghese, Vellore Abstract In an effort to develop better basal insulin with a profile that may cause less hypoglycaemia, ludec an analogue with a decanoic acid side chain
More informationInsulin lispro is a short-acting human
Emerging Treatments and O R I G I N A L A R T I C L E Technologies Optimized Basal-Bolus Therapy Using a Fixed Mixture of 75% Lispro and 25% NPL Insulin in Type 1 Diabetes Patients No favorable effects
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationOlympic diabetes What have we learned over the last decade? Ian Gallen Jephcott Symposium 9 th May 2012
Olympic diabetes What have we learned over the last decade? Ian Gallen Jephcott Symposium 9 th May 2012 Diabetes and exercise Ian Gallen Challenges in the management SR s diabetes prior to 2000 Olympic
More informationPharmacotherapy of Type 2 Diabetes
Pharmacotherapy of Type 2 Diabetes Disclosures I am a member of a Biodel, Lilly, Metavention, NovoNordisk, and VTech Pharma Advisory Boards and have served as a consultant for Merck and Takeda 20 Glucose
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationDiabetes Care 25: , 2002
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs TORBJÖRN LINDSTRÖM, MD 1 CHRISTINA
More informationDoes metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both?
Diabetologia (2013) 56:2378 2382 DOI 10.1007/s00125-013-3026-6 SHORT COMMUNICATION Does metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both? Normand G. Boulé
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationInsulin analogues Das PP, Datta PG
The ORION Medical Journal 2007 Sep;28:497-500 Insulin analogues Das PP, Datta PG Introduction Diabetes mellitus is a very big challenge for our medical science. To overcome this problem we need newer generation
More informationTim Heise 1 Kirstine Stender-Petersen. Leszek Nosek 1 Eric Zijlstra
Clin Pharmacokinet (17) 56:649 66 DOI 1.17/s46-16-473-5 ORIGINAL RESEARCH ARTICLE Pharmacokinetic and Pharmacodynamic Properties of Faster- Acting Insulin Aspart versus Insulin Aspart Across a Clinically
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationDiabetologia 9. Impact of metabolic control in progression of clinical diabetic nephropathy
Diabetologia (1987) 3:82-86 Diabetologia 9 Impact of metabolic control in progression of clinical diabetic nephropathy G. Nyberg a, G. Blohm6 z and G. Nord6n 1 Departments of 1Nephrology and 2Medieine
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationESPEN Congress Madrid 2018
ESPEN Congress Madrid 2018 Dysglycaemia In Acute Patients With Nutritional Therapy Mechanisms And Consequences Of Dysglycaemia In Patients Receiving Nutritional Therapy M. León- Sanz (ES) Mechanisms and
More informationDiabetes Care 25: , 2002
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Absorption and Metabolic Effect of Inhaled Insulin Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients
More informationDiabetes Care 25: , role of sustained hyperglycemia in the development
Pathophysiology/Complications O R I G I N A L A R T I C L E Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients
More informationMetformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11
Metformin Associated Lactic Acidosis Jun-Ki Park 9/6/11 Probably the most common mechanism by which metformin elevates blood lactate is by inducing catecholamine release in those who regulate or prescribe
More informationJARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.
JARDIAMET (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg NAME OF THE MEDICINE JARDIAMET contains two oral antihyperglycaemic
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationEFFECT OF VAGOTOMY AND PYLOROPLASTY: THE ORAL GLUCOSE TOLERANCE TEST
GASTROENTEROLOGY 64: 217-222, 1973 Copyright 1973 by The Williams & Wilkins Co. Vol. 64, No.2 Printed in U.S.A. EFFECT OF VAGOTOMY AND PYLOROPLASTY: THE ORAL GLUCOSE TOLERANCE TEST W, H, HALL, M,D" L.
More informationInsulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
Diabetes, Obesity and Metabolism 14: 859 864, 2012. 2012 Blackwell Publishing Ltd Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type
More informationControl of early-morning hyperglycemia
O R I G I N A L A R T I C L E Prevention of Early-Morning Hyperglycemia in IDDM Patients With Long-Acting Zinc Insulin MARIO PARILLO, MD ANTONIO MURA, MD CIRO IOVINE, MD ANGE1A A. RRVELLESE, MD MARIO IAVICOLI,
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More informationPharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol
Br. J. clin. Pharmac. (1984), 17, 97S-12S Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol H. SPAHN', W. KIRCH2,. MUTSCHLR',.. OHNHAUS2, N. R. KITFRINGHAM2,
More informationCase Study: Competitive exercise
Case Study: Competitive exercise 32 year-old cyclist Type 1 diabetes since age 15 Last HbA1 54 No complications and hypo aware On Humalog 8/8/8 and Levemir 15 Complains about significant hypoglycaemia
More informationR. B. VAUGHAN. M.B., B.S., Ph.D. Clinical Research Department, Pfizer Limited tion of the indanyl ester. Serum levels were also
Postgraduate Medical Journal (July 1972) 48, 422-426. The pharmacokinetics of an oral form of carbenicillin in patients with renal failure R. R. BAILEY* M.D.(N.Z.), M.R.A.C.P., M.R.C.P. J. B. EASTWOOD
More informationThe enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans
The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Seoul National University College of Medicine Plasma glucose
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationRenal Physiology. April, J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine.
Renal Physiology April, 2011 J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine. Office : Room 105, Physiology Unit. References: Koeppen B.E. & Stanton B.A. (2010).
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationDiabetes Mellitus. Eiman Ali Basheir. Mob: /1/2019
Diabetes Mellitus Eiman Ali Basheir Mob: 091520385 27/1/2019 Learning Outcomes Discuss the WHO criteria for Diabetes Mellitus diagnosis Describe the steps taken to confirm diagnosis Interpret GTT. Discuss
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationA Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
Clin Pharmacokinet (7) :9 DOI.7/s---7 REVIEW ARTICLE A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use Hanne Haahr Edmond
More informationOptimal Provision of Daytime NPH Insulin in Patients Using the Insulin Analog Lispro. Diabetes Care 21: , 1998
E m e r g i n g T r e a t m e n t s a n d T e c h n o l o g i e s N A L A R T I C L E Optimal Provision of Daytime NPH Insulin in Patients Using the Insulin Analog Lispro ABU BAKER E. AHMED, MRCP PHILIP
More informationConfusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators
4319DSTXXX10.1177/1932296813514319Journal of Diabetes Science and TechnologyWalsh et al 014 Commentary Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by
More informationEuglycaemic glucose clamp: what it can and cannot do, and how to do it
Received: 14 March 2016 Revised: 5 June 2016 Accepted: 6 June 2016 DOI 10.1111/dom.12703 REVIEW ARTICLE Euglycaemic glucose clamp: what it can and cannot do, and how to do it Tim Heise MD 1 Eric Zijlstra
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationGlimepiride Improves Both First and Second Phases of Insulin Secretion in Type 2 Diabetes. Diabetes Care 25: , 2002
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Glimepiride Improves Both First and Second Phases of Insulin Secretion in Type 2 Diabetes MARY KORYTKOWSKI, MD 1 ABRAHAM THOMAS, MD 2
More informationSwitching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes
Diabetes Management Switching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes Myrey Siuffi D* ABSTRACT Introduction: Degludec (Ideg) is an ultra-long
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationGlucagon secretion in relation to insulin sensitivity in healthy subjects
Diabetologia (2006) 49: 117 122 DOI 10.1007/s00125-005-0056-8 ARTICLE B. Ahrén Glucagon secretion in relation to insulin sensitivity in healthy subjects Received: 4 July 2005 / Accepted: 12 September 2005
More informationEFFICACY AND METABOLIC EFFECTS OF METFORMIN AND TROGLITAZONE IN TYPE II DIABETES MELLITUS
EFFICACY AND METABOLIC EFFECTS OF METFORMIN AND TROGLITAZONE IN TYPE II DIABETES MELLITUS EFFICACY AND METABOLIC EFFECTS OF METFORMIN AND TROGLITAZONE IN TYPE II DIABETES MELLITUS SILVIO E. INZUCCHI, M.D.,
More informationSevere Hypoglycemia Is a Serious Complication and Becoming an Economic Burden in Diabetes
Original Article Complications http://dx.doi.org/10.4093/dmj.2012.36.4.280 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Severe Hypoglycemia Is a Serious Complication
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationThe kidney. (Pseudo) Practical questions. The kidneys are all about keeping the body s homeostasis. for questions Ella
The kidney (Pseudo) Practical questions for questions Ella (striemit@gmail.com) The kidneys are all about keeping the body s homeostasis Ingestion Product of metabolism H 2 O Ca ++ Cl - K + Na + H 2 O
More informationDecreased Non-Insulin Dependent Glucose Clearance Contributes to the Rise in FPG in the Non-Diabetic Range.
Diabetes Care Publish Ahead of Print, published online November 13, 2007 Decreased Non-Insulin Dependent Glucose Clearance Contributes to the Rise in FPG in the Non-Diabetic Range. Rucha Jani, M.D., Marjorie
More information